Valuation: EyePoint, Inc.

Market Cap 34.48M 30.8M 28.29M 25.7M 48.25M 3.27B 49.47M 338M 136M 1.72B 129M 127M 5.46B P/E 2026 *
-0.11x
P/E 2027 * -0.2x
Enterprise Value -296M -265M -243M -221M -415M -28.06B -425M -2.9B -1.17B -14.81B -1.11B -1.09B -46.95B EV / Sales 2026 *
-174x
EV / Sales 2027 * -45.5x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: EyePoint, Inc.

1 day-0.73%
1 week+10.10%
Current month+14.78%
1 month-87.70%
3 months-96.78%
6 months-97.00%
Current year-97.81%
1 week 0.34
Extreme 0.3446
0.42
1 month 0.34
Extreme 0.3446
3.57
Current year 0.34
Extreme 0.3446
18.87
1 year 0.34
Extreme 0.3446
19.11
3 years 0.34
Extreme 0.3446
30.99
5 years 0.34
Extreme 0.3446
30.99
10 years 0.34
Extreme 0.3446
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-139,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%+10.10%-96.79%-94.84% 34.48M
+1.68%+9.94%+57.20%+148.21% 1,255B
+2.03%-0.95%+42.90%+75.88% 641B
+0.67%-0.14%+34.93%+102.23% 505B
+0.81%-1.25%+49.17%+66.06% 381B
+1.87%+2.01%+75.38%+39.94% 357B
+1.52%+3.34%+31.59%+58.52% 303B
+1.53%+9.42%+11.48%+35.91% 286B
+2.33%+2.97%+55.67%+70.93% 249B
+2.91%+5.27%+37.21%+105.26% 208B
Average +1.65%+3.60%+29.88%+60.81% 418.53B
Weighted average by Cap. +1.85%+3.68%+47.08%+93.97%

Financials

2026 *2027 *
Net sales 1.7M 1.52M 1.4M 1.27M 2.38M 161M 2.44M 16.68M 6.71M 85.14M 6.39M 6.25M 270M 3.85M 3.44M 3.16M 2.87M 5.39M 365M 5.52M 37.71M 15.17M 192M 14.45M 14.14M 610M
Net income -325M -291M -267M -242M -455M -30.81B -467M -3.19B -1.28B -16.26B -1.22B -1.19B -51.54B -198M -177M -163M -148M -277M -18.78B -284M -1.94B -781M -9.91B -744M -728M -31.42B
Net Debt -331M -295M -271M -246M -463M -31.33B -475M -3.24B -1.3B -16.53B -1.24B -1.21B -52.41B -210M -187M -172M -156M -294M -19.87B -301M -2.06B -827M -10.49B -787M -771M -33.25B
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
04/11/26 $0.3999 +6.70% 3,512,441
02/11/26 $0.3748 +7.58% 6,327,727
30/10/26 $0.3484 -8.32% 6,119,164
29/10/26 $0.3800 +0.69% 6,601,723
28/10/26 $0.3774 +3.91% 6,504,012
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.3999USD
Average target price
8.438USD
Spread / Average Target
+2,009.90%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - EyePoint, Inc.
  1. Stock Market
  2. Stocks
  3. EYPT Stock